FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that... FT516 is currently being tested against acute myeloid leukemia, B-cell lymphoma, and solid tumors in combination with other compounds.
- Mechanism
- Curator reviewed
FT516 contains engineered NK cells expressing CD16, which are activated through binding of the Fc portion of IgG antibodies. When activated, these NK Cells destroy antibody-coated target cells while also secreting additional cytokines and recruiting T-cells. The mechanism, referred to as antibody-dependent cellular cytotoxicity (ADCC), depends on the stable and effective expression of CD16 on the NK cells.
- Code names
- FT516
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with FT516, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account